








THERAPEUTIC AREA	DISCOVERY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PHASE 4 / REGULATORY	LCM
 Immunology	++	PIDD: recIG (Plasma-derived Ig enriched with recombinant polyclonal antibodies) <i>PIDD: Primary immunodeficiency disorder Ig: Immunoglobulin</i>			PIDD: IVIG-PEG CLL: Xembify® <i>IVIG: Intravenous immunoglobulin CLL: Chronic lymphocytic leukemia</i>	PIDD: Xembify® Europe PIDD: Xembify® Bi-weekly dose PIDD: Yimmugo® (IVIG-G Next Gen) <small>Commercialization started</small>	PIDD: Xembify® Prefilled syringes
 Hepatology / Intensive Care	++				DECOMPENSATED CIRRHOSIS: Albumin 20% (PRECIOSA trial) ACUTE-ON-CHRONIC LIVER FAILURE: Albumin 5% (APACHE trial)		NEW ALBUMIN CONTAINER: Albutein FlexBag™
 Pulmonology		NON-CYSTIC FIBROSIS BRONCHIECTASIS: Alpha₁-antitrypsin (AAT)		ALPHA ₁ -ANTITRYPSIN DEFICIENCY: AAT 15% (subcutaneous)		ALPHA ₁ -ANTITRYPSIN DEFICIENCY: Prolastin-C® Europe (SPARTA trial)	ALPHA ₁ -ANTITRYPSIN DEFICIENCY: Prolastin® EU 4-5gr vials
 Hematology	+	SEPSIS: Antithrombin-III (AT-III)*			CONGENITAL DEFICIENCY & SEVERE HYPOFIBRINOGEN: Fibrinogen ACQUIRED FIBRINOGEN DEFICIENCY: Fibrinogen	CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) [REFRACTORY PATIENTS]: Fostamatinib** ITP: Yimmugo® (IVIG-G Next Gen) <small>Commercialization started</small>	
 Neurology	+++	CADASIL AKST1220 <i>CADASIL: Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy</i>		ALZHEIMER'S DISEASE: GRF6019 PARKINSON'S DISEASE WITH DEMENTIA: GRF6021 ALZHEIMER'S DISEASE: ABvac40 PARKINSON'S DISEASE: AKST4290	ALZHEIMER'S DISEASE: AMBAR® Procedure (AMBAR-Next® Trial)		
 Infectious Diseases	+++	HEPATITIS B INFECTION: GIGA 2339 (Recombinant hyperimmune Ig)			SEVERE COMMUNITY-ACQUIRED PNEUMONIA (SCAP): Trimodulin (IG-M) HUMAN CYTOMEGALOVIRUS (CMV) INFECTION: Cytotec® Pregnancy (Polyclonal anti-CMV immunoglobulins)		
 Further Therapeutic Opportunities	++	CANCER: GIGA 564 (Anti-CTLA-4 mAb) CANCER: GIGA 2328 (Anti-CTLA-4 mAb) <i>mAb: Monoclonal antibody</i>	DRY EYE DISEASE: OSIG (Ocular surface immunoglobulin)***	nAMD and DR: AKST4290 END STAGE RENAL DISEASE: AKST1210 <i>nAMD: Neovascular age-related macular degeneration DR: diabetic retinopathy</i>		VARIOUS HEMATOLOGIC AND WOUND-HEALING INDICATIONS: VistaSeal™/VeraSeal™ (Fibrin Sealant) Biosurgery Pediatric Use	

COLOR KEY AND NOTES

Plasma projects
 Non-plasma projects
 Biotest Collaborations

*Partnership with Endpoint Health; ** Licensed rights from Rigel Pharmaceuticals in EU and other countries; ***Global collaboration and licensing agreement with Selagine, Inc.